Multiple Sclerosis (MS) Therapy
TYSABRI® (natalizumab) is indicated for treatment of: (1) Multiple Sclerosis: as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis. Tysabri increases the risk of PML. When initiating and continuing treatment with Tysabri, physicians should consider whether the expected benefit of Tysabri is sufficient to offset this risk; (2) Crohn’s Disease (CD): Inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of tumor necrosis factor-α.
Visit http://www.tysabri.com for more information.
A clinical study of the efficacy of natalizumab on reducing disability progression in subjects with secondary progressive MS is in Phase 3b clinical trial and ongoing.
Please see full Prescribing Information (PDF), including Boxed Warning and Patient Medication Guide (PDF).
TYSABRI® is marketed and distributed solely by Biogen. Perrigo receives royalties on in-market sales.